BDKRB2 and infection: Confirming the results of pre-treatment, post-infection treatment with the B2R-antagonist also attenuated the cytopathic effect of SARS-CoV-2 (Fig. 2B) and reduced the number of PFU in a plaque assay on Vero-E6 cells by 84% (Fig. 2C).